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Abstract
The current epidemic of non-alcoholic fatty liver disease 
(NAFLD) is reshaping the field of hepatology all around 
the world. The widespread diffusion of metabolic risk 
factors such as obesity, type2-diabetes mellitus, and 
dyslipidemia has led to a worldwide diffusion of NAFLD. In 
parallel to the increased availability of effective anti-viral 
agents, NAFLD is rapidly becoming the most common 
cause of chronic liver disease in Western Countries, and 
a	similar	trend	 is	expected	 in	Eastern	Countries	 in	the	
next years. This epidemic and its consequences have 
prompted experts from all over the word in identifying 
effective strategies for the diagnosis, management, 
and treatment of NAFLD. Different scientific societies 
from Europe, America, and Asia-Pacific regions have 
proposed	guidelines	based	on	the	most	recent	evidence	
about NAFLD. These guidelines are consistent with the 
key elements in the management of NAFLD, but still, 
show significant difference about some critical points. 
We reviewed the current literature in English language 
to identify the most recent scientific guidelines about 
NAFLD with the aim to find and critically analyse the 
main differences. We distinguished guidelines from 5 
different scientiic societies whose reputation is worldwide 
recognised and who are representative of the clinical 
practice in different geographical regions. Differences 
were noted in: the definition of NAFLD, the opportunity 
of NAFLD screening in high-risk patients, the non-
invasive test proposed for the diagnosis of NAFLD and the 
identification of NAFLD patients with advanced fibrosis, 
in the follow-up protocols and, finally, in the treatment 
strategy (especially in the proposed pharmacological 
management). These difference have been discussed 
in the light of the possible evolution of the scenario of 
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Core tip: Non-alcoholic fatty liver disease (NAFLD) is 
becoming the most common cause of chronic liver dis-
ease. As such, an increasing number of scientiic reports 
are investing this condition. To translate these evidence 
into clinical practice, international scientiic societies have 
proposed guidelines for the management of NAFLD. In 
this review, we will critically analyse both the converging 
and diverging points in the current clinical guidelines of 
NAFLD, with a particular focus on the diagnostic and 
therapeutic aspects.
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current 
guidelines for the management of non-alcoholic fatty liver 
disease: A systematic review with comparative analysis. World J 
Gastroenterol 2018; 24(30): 3361-3373  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v24/i30/3361.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v24.i30.3361
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) includes a 
spectrum of disorders ranging from the simple fatty 
liver to non-alcoholic steatohepatitis, with increasing 
ibrosis leading to cirrhosis[1]. The prevalence of NAFLD 
is alarmingly growing worldwide in adult and children/
adolescent populations, with a bidirectional association 
between NAFLD and metabolic syndrome[2]. Obesity, 
insulin resistance, type 2 diabetes mellitus, and dyslipi­
demia are the most relevant metabolic conditions related 
to this spectrum of diseases
[1,2]
. 
Clinicians and researchers from several scientific 
Associations worldwide put significant efforts into 
increasing knowledge and developing high-quality In-
ternational Guidelines to improve the management 
of NAFLD patients in clinical practice. Multidisciplinary 
panels of experts in different continents have performed 
systematic analysis and review of the literature on 
speciied topics in the last years. These efforts have led 
to the creation and publication of various Guidelines.
This paper aims to review and compare the most 
recently published International Guidelines for the diag­
nosis and the management of NAFLD in adult popu-
lations, to critically evaluate similarities and discrepancies. 
In particular, we tried to analyse some critical questions 
and challenges for clinicians in real life.
LITERATURE SEARCH
We performed a database search on PubMed selecting 
papers published between January 2016 and January 
2018 in the English language. The following keywords 
and terms were considered: (1) Fatty liver disease 
((“fatty liver”[MeSH Terms] OR (“fatty”[All Fields] 
AND “liver”[All Fields]) OR “fatty liver”[All Fields]) AND 
(“disease”[MeSH Terms] OR “disease”[All Fields])) AND 
guideline (“guideline”[Publication Type] OR “guidelines 
as topic”[MeSH Terms] OR “guideline”[All Fields]) 
AND management (“organization and administration”
[MeSH Terms] OR (“organization”[All Fields] AND 
“administration”[All Fields]) OR “organization and 
administration”[All Fields] OR “management”[All Fields] 
OR “disease management”[MeSH Terms] OR (“disease”
[All Fields] AND “management”[All Fields]) OR “disease 
management”[All Fields]); (2) Fatty liver disease AND 
recommendation ((“fatty liver”[MeSH Terms] OR (“fatty”
[All Fields] AND “liver”[All Fields]) OR “fatty liver”[All 
Fields]) AND (“disease”[MeSH Terms] OR “disease”[All 
Fields])) AND recommendation[All Fields]; (3) Fatty 
liver disease and position paper ((“fatty liver”[MeSH 
Terms] OR (“fatty”[All Fields] AND “liver”[All Fields]) OR 
“fatty liver”[All Fields]) AND (“disease”[MeSH Terms] 
OR “disease”[All Fields])) AND (position[All Fields] AND 
(“paper”[MeSH Terms] OR “paper”[All Fields])).
According to this criteria, 119 papers were identiied. 
As a second step, we excluded papers which were not 
pertinent to any of the following criteria: (1) Clinical 
Guidelines related to diagnosis and management of 
NAFLD in the adult population; (2) clinical Guidelines 
published by Governmental agencies and Scientiic Asso­
ciations.
According to the selection criteria, out of 119 results 
of PubMed research, 5 Guidelines were inally included in 
this analysis. These guidelines are strictly focused on the 
topic of diagnosis and management of NAFLD in adult, 
excluding pediatric populations and special groups. In 
detail, the ive selected papers included (from the oldest 
to the newest date of publication): (1) “EASL­EASD­
EASO Clinical Practice Guidelines for the management 
of non­alcoholic fatty liver disease” by the European 
Association for the Study of The Liver (EASL), published 
in 2016[3]; (2) “Nonalcoholic fatty liver disease (NAFLD): 
Assessment and management” by the National Institute 
for Health and Care Excellence (NICE), published in 
2016[4]; (3)“Asia­Paciic Working Party on Non­Alcoholic 
Fatty Liver Disease guidelines” published in 2017[5,6]; (4) 
Italian Association for the Study of the Liver (AISF). AISF 
position paper on nonalcoholic fatty liver disease (NAFLD): 
Updates and future directions, published in 2017[7]; (5) 
“The diagnosis and Management of Nonalcoholic Fatty 
Liver Disease: Practice Guidance From the American 
Association for the Study of Liver Diseases” published in 
2018[8]. 
OPEN QUESTIONS
Deinition, classiication, and diagnostic criteria of 
NAFLD
Definition and classification: A definition of NAFLD 
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is reported in all Guidelines (Table 1). The characteristic 
points of NAFLD definition include (1) the evidence 
of excessive hepatic fat accumulation in the liver par-
enchyma (detected by imaging techniques or histology); 
(2) the absence of other secondary causes of hepatic 
fat. Out of them, to strictly define NAFLD patients a 
signiicant ongoing or recent alcohol consumption have 
to be excluded in all recommendation[3­8].
All recommendations identify some different clinical-
pathological entities, according to the progression of 
hepatic histological changes. Simple steatosis and 
non-alcoholic steatohepatitis (NASH) are defined in 
all guidelines
[3­8]
. In detail simple steatosis, also called 
non-alcoholic fatty liver (NAFL) includes all of the case 
characterized by steatosis with minimal or absent lobular 
inflammation. On the contrary, NASH is characterized 
by hepatocyte ballooning degeneration, diffused lobular 
inlammation and ibrosis (Figure 1)
Additionally, EASL Asia­Pacific Guidelines and AISF 
position paper also underline the problem of NAFLD­
related HCC, potentially occurring in patients with NAFLD 
but without cirrhosis[9,10]. 
Diagnostic criteria: The role of alcohol: The 
agreement between the different guidelines is not 
complete when defining the threshold dose of alcohol 
consumption. As shown in Table 1, EASL[3], NICE, and 
AISF guidelines
[3,4,7]
 consider as significant an alcohol 
consumption > 30 g/d in men and > 20 g/d in women. 
The AASLD guidance
[8] indicate the reasonable threshold 
for signiicant alcohol consumption > 21 standard drink 
on average per week in men and > 14 in women. For 
Asia­Paciic Guidelines[5] a signiicant alcohol intake was 
considered > 7 standard alcoholic drinks/week (70 g 
ethanol) in women and > 14 (140 g) in men. 
Who should be screened for NAFLD?
According to the screening programs adopted for other 
diseases, systematic screening has to be performed 
for significant health problem with available diagnostic 
facilities and accepted treatment. Also, there should be 
recognisable latent or early symptomatic stage, identi­
fiable with sensitive tests. To adequately perform a 
screening program, the natural history of the disease 
should be understood, and the economic burden should 
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EASL NICE Asia-Paciic AISF AASLD
Required criteria  Steatosis in > 5% of 
hepatocytes by either 
imaging or histology
Excessive fat in the liver Hepatic steatosis by either 
imaging or histology
Hepatic steatosis on 
either imaging or 
histology
Evidence of hepatic 
steatosis either by 
imaging or histology
No other causes of 
steatosis
No other causes of 
steatosis
No other causes of 
steatosis
No other causes of 
steatosis
No other causes of 
steatosis
Insulin resistance No signiicant alcohol 
consumption
No signiicant alcohol 
consumption
No signiicant alcohol 
consumption
No signiicant alcohol 
consumption





30 g/d 30 g/d 2 standard drink/d 30 g/d 21 standard drink/wk




20 g/d 20 g/d 1 standard drink/d 20 g/d 14 standard drink/wk
70 g/wk 196 g/wk
Table 1  Diagnostic criteria for non-alcoholic fatty liver disease according to the various guidelines
EASL: European Association for the Study of the Liver; NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the study of 
the Liver; AASLD: American Association for the Study of Liver Diseases; MRI: Magnetic resonance imaging.
50 μm 50 μm
A B
Figure 1  Main difference between non-alcoholic fatty liver and non-alcoholic steatohepatitis. A: Non-alcoholic fatty liver; B: Non-alcoholic steatohepatitis. 
NAFL is characterized by minimal inlammatory iniltrate without hepatocyte ballooning (arrow). Instead, NASH is associated with lobular inlammatory iniltrate and 
hepatocyte degeneration (arrow). NAFL: Non-alcoholic fatty liver; NASH: Non-alcoholic steatohepatitis.
Leoni	S	et	al . NAFLD guidelines
3364 August 14, 2018|Volume 24|Issue 30|WJG|www.wjgnet.com
er dependency remains
[15]. NICE guidelines propose 
to use liver ultrasound to detect hepatic steatosis for 
children with metabolic syndrome and type 2 diabetes 




On the other hand, magnetic resonance imaging 
(MRI), either by proton density fat fraction (1H-MRS) or 
spectroscopy, remains the gold standard to assess and 
quantify hepatic steatosis, detecting the amount of liver 
fat as low as 5%­10%, its use in the clinical practice is 
still limited. In fact, despite its robust accuracy, its limited 
availability, high costs and a long time of execution, 
make the procedure not recommended in the daily 
clinical setting
[17]. Asia­Pacific guidelines specify that 
1H­MRS is the best option to quantify even moderate 
changes in liver fat content in clinical trials, considering 
its high sensitivity compared to histological-proven liver 
fat reversal. Similarly, EASL guidelines highlight its role, 
primarily as screening imaging examination for clinical 
trials and experimental studies
[3]
.
Another imaging technique used to quantify liver fat 
content is the ultrasonography­based transient elasto­
graphy (TE) using continuous attenuation parameter 
(CAP). This promising tool has shown a good sensitivity, 
measuring simultaneously liver stiffness, potentially 
evaluating NAFLD severity at the same setting
[13]
. How-
ever, despite its low cost and rapidity of execution, its 
role in the clinical practice has still to be defined. In 
fact, EASL guidelines specify that TE has never been 
compared with hepatic steatosis measured by 1H-MRS 
and there are limited data about its ability to discriminate 
different histological patterns
[3]
. On the other hand, Asia-
Pacific guidelines propose CAP as a useful screening 
tool for NAFLD diagnosis, as well as for demonstrating 
improvement in hepatic steatosis after lifestyle inter-
vention and body weight reduction[5].
Conventional liver biochemistry: Although NAFLD 
may present by standard laboratory liver tests, frequently 
a slight increase of aspartate aminotransferase (AST) 
or alanine aminotransferase (ALT) or gamma-glutamyl 
transpeptidase (GammaGT) is observed. However, all 
the guidelines agree that normal levels of liver enzymes 
may not exclude NAFLD, being a not sensitive screening 
be suitable.
The international guidelines partially diverge about 
this topic. This disagreement derives from essential con-
siderations regarding natural history, special groups, 
diagnosis, and therapy: (1) NAFLD in a common cause 
of chronic liver disease in general population but cause 
severe liver disease in a small proportion of affected 
people
[1]
; (2)Type Ⅱ diabetes patients have higher preva­
lence of NAFLD, NASH and advanced fibrosis[11-13]; (3) 
There is a current lack of effective drug treatment; (4) 
Liver biopsy is a procedure with related risks; (6) Few 
cost­effective analysis are available[14].
All these considerations imply a different approach 
to screening in NAFLD by the Scientific Societies. Only 
EASL, NICE Asia­Pacific Guidelines[3­5] recommend 
screening respectively in particular, “high-risk” groups 
(Table 2). On the contrary, AASLD guidelines emphasise 
that, to date, there is no evidence of cost-effectiveness 
to support a NAFLD screening in adults even if they 
have several metabolic risk factors, instead suggesting a 
concept of “vigilance” in these populations
[8]
.
Which noninvasive test(s) should be used to diagnose 
NAFLD?
Worldwide guidelines agree that, whenever NAFLD is 
suspected, the initial diagnostic workup should include 
a noninvasive imaging examination to conirm the pre­
sence of steatosis and general liver biochemistry[3­8]. 
Non­invasive assessment should aim irst of all to identify 
NAFLD among patients with metabolic risk factors, and 
then to monitor disease progression and treatment 
response, identifying patients with the worst prognosis
[3]
.
Imaging: There is a consensus for using abdominal 
ultrasound (US) as the irst­line examination to identify 
liver steatosis in patients with increased liver blood 
exams or suspected NAFLD, in daily clinical practice 
(Figure 2). The main advantages of US derive from its 
broad availability and low cost. However, its sensitivity 
among morbidly obese patients (BMI > 40 kg/m2) is low, 
and it may miss the diagnosis when the liver hepatic fat 
content is < 20%[15,16]. Despite these limitations, EASL 
and AISF underline how ultrasound can significantly 
assess moderate and severe steatosis, even if an observ­
EASL NICE Asia-Paciic AISF AASLD
Systematic 
screening




Yes Yes Yes Not mentioned No1
Obesity Obesity Obesity




Yes liver enzymes No liver enzymes No liver enzymes
Yes ultrasonography Yes ultrasonography
Yes transient elastography
Table 2  Comparative analysis of the recommendations regarding the screening for non-alcoholic fatty liver disease
1"Active surveillance" (but not screening) suggested for patients with type Ⅱ diabetes mellitus. EASL: European Association for the Study of the Liver; 
NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the Study of the Liver; AASLD: American Association for the Study 
of Liver Diseases.
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Moreover, laboratory alterations may hide another 
cause of liver disease, in which steatosis is a coexisting 
condition. On the other hand, detection of abnormalities 
of laboratory exams (such as ferritin or autoantibodies) 
not always relects the presence of another liver disease, 
but could be an epiphenomenon of NAFLD with no 
further clinical signiicance.
In particular, AASLD guidelines underline that ele-
vate serum ferritin and low titers of autoimmune anti-
bodies (especially antinuclear and anti­smooth muscle 
antibodies) are common features among NAFLD 
patients
[18,19]
, and may not automatically indicate the 




Which is the role of diagnostic and prognostic scores?
Noninvasive predictor biomarkers and scores of 
steatosis and steatohepatitis: The current absence 
of a highly specific and sensitive noninvasive marker 
predicting inflammation and fibrosis is leading to a 
considerable interest in the identiication of new markers 
of disease progression and to the development of clinical 
scores of disease severity.
To assess the presence of steatosis, EASL, Asia­
Pacific, and Italian guidelines mention the Fatty Liver 
Index (FLI)
[20]
 and the NAFLD liver fat score
[21]. Both of 
these scores are easily calculated using common blood 
exams and simple clinical information. In detail, FLI is 
calculated from serum triglyceride, body mass index, 
waist circumference, and gamma-glutamyltransferase
[20]
, 
while NAFLD liver fat score is calculated evaluating the 
presence/absence of metabolic syndrome and type 2 
diabetes, fasting serum insulin, and aminotransferases[21].
They have been validated in a cohort of severely obese 
patients and the general population, reliably predicting 
the presence of steatosis, but not its severity[22]. On 
the contrary, the AASLD guidelines underline that only 
inlammation and ibrosis dictate the prognosis of NAFLD 
patients and, consequently, highlight the lack of evidence 
Figure 2  Aspects of liver steatosis according to the different imaging techniques. In normal ultrasound examination liver parenchyma is isoechoic to the renal 
parenchyma in normal conditions (A1), becoming hyperechoic in presence of liver steatosis (A2). In comparison to a normal liver (B1), a fatty liver appears hypodense 
compared to the spleen and to the hepatic veins (B2) in computed tomography scans. Finally, in the setting of a severe steatosis, the magnetic resonance signal has 
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of the usefulness of quantifying hepatic steatosis in 
the routine clinical setting. Instead, AASLD guidelines 
underline that the simultaneous presence of several 
metabolic diseases is the most potent predictor of hepatic 
inflammation and adverse outcome in patients with 
NAFLD.
The cytokeratin­18 fragment is currently the most stud­
ied biomarker to assess the presence of inflammation. 
Its circulating levels have been largely investigated as a 
signal of hepatocellular apoptotic activity and therefore as 
a characteristic feature of NASH
[23]
. Its role is addressed 
both by Asia­Pacific and EASL guidelines, which agree 
that the current evidence does not support its use in 
clinical practice and that more studies are needed
[3,5]
. In 
particular, Asia­Paciic guidelines highlight how increased 
levels of cytokeratin­18 have good predictive value for 
NASH vs normal livers but do not differentiate NASH vs 
simple steatosis
[24,25]. On the other hand, EASL guidelines 
specify that has been demonstrated that cytokeratin­18 
serum levels decrease parallel with histological improve-




To conclude, guidelines agree that noninvasive tests 
for detecting NASH and distinguishing it from simple 
steatosis are not currently available and that liver biopsy 
remains necessary to detect hepatocyte ballooning and 
lobular inlammation[3­8].
Noninvasive assessment of advanced ibrosis: Liver 
ibrosis is considered the leading prognostic factor among 
patients with NAFLD because of its strong correlation with 
survival rate and liver-related outcomes
[27]
. Therefore, 
NAFLD patients with advanced fibrosis need a closer 
monitoring and a rigorous adherence to treatment. 
However, to date, no methods easily performed in daily 
clinical practice and with a high predictive value for dif-
ferentiating grades of liver ibrosis have been identiied.
Different tools have been investigated at this pur­
pose, including noninvasive scores (NAFLD ibrosis score, 
Fibrosis 4 calculator, AST/ALT ratio index), serum bio­
markers (ELF panel, Fibrometer, Fibrotest, Hepascore) 
and imaging techniques, such as transient elastography, 




According to the NICE guideline, the enhanced 
liver ibrosis (ELF) blood test has shown the best cost­
effectiveness in identifying patients with advanced fi-
brosis stages[29] and therefore should be offered to all 
patients with an incidental diagnosis of NAFLD
[4]
. On 
the other hand, EASL and Italian guidelines suggest the 
use of NAFLD ibrosis score (NFS) and Fibrosis 4 calcu­
lator (FIB­4) as noninvasive scores to identify patients 
with different risk of advanced fibrosis[3,7]. These two 
scores have been validated in various ethnically NAFLD 
patients, predicting liver and cardiovascular-related 
mortality
[30]
. Moreover AASLD guidelines highlight that 
in a recent study both NFS and FIB­4 have shown 
the best predictive value for advanced fibrosis among 
histological proven NAFLD patients in comparison with 
other scores
[28]. EASL guidelines underline that NFS has 
a stronger negative predictive value for advanced ibrosis 
than the corresponding positive predictive value
[30]
. 
Hence, it should be used for excluding the presence of 
advanced ibrosis better than stratifying NAFLD patients 
on different ibrosis stages[3].
Transient elastography has been recently approved 
by US Food and Drug Administration to investigate adult 
and pediatric patients with liver disease. Its cut-off value 
for advanced fibrosis for adults with NAFLD has been 
established to 9.9 KpA with 95% sensitivity and 77% 
speciicity[31]. In particular, elastography score has been 
shown to have good diagnostic accuracy for the presence 
of clinically significant fibrosis, with an AUROC of 0.93 
(95%CI: 0.89­0.096) for advanced ibrosis (≥ F3) and 
cirrhosis, and with a negative predictive value of 90% 
in ruling out cirrhosis when using a cut­off of 7.9 kPa. 
However, the ability in differentiating between F2 and F3 
ibrosis seems less robust. Because of this high rate of 
false­positive results, EASL and Asia­Pacific guidelines 
point out that its low specificity limits its use in daily 
practice in diagnosing advanced grade of fibrosis and 
cirrhosis, as well as by a high failure rate[5]. Moreover 
considering the unreliable results among patients with 
high BMI and thoracic fold thickness, EASL guidelines 
highlight that it should not be used alone as first­line 
detection tool to identify advanced ibrosis or cirrhosis[3]. 
In this setting, its poor performance can be improved by 
using M or XL­probe, increasing the success rate[32,33].
American guidelines underline the vital role of magnet-
ic resonance elastography (MRE) in identifying different 
degrees of fibrosis in patients with NAFLD, performing 
better than transient elastography for recognising inter­
mediate stage of ibrosis, but showing a same predictive 
value for advanced ibrosis stages[34]. Therefore AASLD 
guidelines conclude that MRE and transient elastography 
are both useful tools for identifying NAFLD patients with 
advanced liver ibrosis.
On the other hand, shear wave elastography, in the 
same way as transient elastography, seems to be inap­
propriate to discriminate between intermediate stages 
of fibrosis and provide reliable results only in 73% of 
patients with BMI ≥ 30 kg/m2[35].
Which are the best diagnostic algorithms and follow-up 
strategies?
The optimal strategy for stratifying NAFLD patients 
and follow disease progression has not been yet estab­
lished. According to EASL and Italian guidelines, the 
combination of noninvasive scores (NFS and FIB­4) 
and transient elastography should be used to identify 
patients at low risk of advanced liver disease and for 
clinical decision­making. Moreover, this combination 
may instead identify patients who should undergo a 
liver biopsy to conirm advanced ibrosis, and in whom 
a more intensive approach is needed)
[3,7]
. Noninvasive 
serum scores should be calculated for every patient with 
Leoni	S	et	al . NAFLD guidelines
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NAFLD to exclude the presence of signiicant ibrosis. If it 
cannot be ruled out, then transient elastography should 
be performed. Hence, if advanced ibrosis is suspected, 
liver biopsy should be performed for inal diagnosis[3,7]. 
Moreover, a clinical, laboratory and instrumental follow­
up for noninvasive monitoring of fibrosis, is suggested 
every two years for NAFLD patients with normal liver 
enzymes and low risk of advanced ibrosis. Patients with 
evidence of NASH or ibrosis should be screened annually 




Similarly, the AASLD guidelines consider NFS, 
FIB­4, transient elastography, and MRE as the first­
line examination to detect patients with advanced fi-
brosis[8]. Differently from the EASL guidance, however, 
no diagnostic algorithms or follow up strategies are 
provided.
The Asia­Paciic guidelines also agree that combined 
use of serum tests and imaging tools may offer more 
reliable information than using either method alone[6]. 
However, they do not specify which noninvasive test is 
best.
According to the NICE guidelines, every patient with 
an incidental finding of NAFLD should be screened for 
advanced ibrosis by ELF blood test. If negative, it should 
be repeated every three years for adults and two years 
for children. Moreover, children and young people with 
type 2 diabetes mellitus or metabolic syndrome, but 
without steatosis at ultrasound examination, should be 
reevaluated every three years
[4]
.
Who should undergo liver biopsy?
To date, liver biopsy is the gold standard for diagnosing 
NASH and staging liver fibrosis, despite several limi­
tations such as sampling error, variability in interpretation 
by pathologists, high cost and patient discomfort[36]. 
The “NAFLD Activity Score” (NAS)
[37]
 and the “Stea-
tosis Activity Fibrosis” (SAF) scoring system[38] are 
recommended to assess disease activity
[8]
.
Except for the NICE guidelines (which do not provide 
speciic indications about which patients should undergo 
liver biopsy), all of the remaining guidelines substantially 
agree that conirmatory liver biopsy should not be per­
formed in every NAFLD patients. Instead, it should be 
reserved for the following two situations: (1) Uncertain 
diagnosis; (2) suspect of NAFLD-related advanced liver 
disease.
The AASLD guidelines suggest to perform liver bi­
opsy in patients with metabolic syndrome who are at 
increased risk of liver inlammation, or when NFS, FIB­4 
or liver stiffness measured by transient elastography or 
MRE suggest the presence of advanced liver fibrosis. 
In that case, patients would beneit the most from diag­
nosis, obtaining crucial prognostic information[8].
Similarly, EASL and Italian guidelines recommend 
performing a liver biopsy when both serum and imaging 
noninvasive tools show a medium/high risk of advanced 
liver disease, with the aim to confirm the presence of 
advanced liver fibrosis. Furthermore, they underline 
that in selected NAFLD patients at high risk of disease 
progression, the repetition of liver biopsy should be con­
sidered case­by­case every ive years[3,7]. On the other 
hand, the Asia­Pacific guidelines recommend biopsy 
only when a competing aetiology of chronic liver disease 
cannot be excluded just by laboratory exams and per­




How to treat NAFLD?
Lifestyle changes: Lifestyle modification consisting of 
diet, exercise, and weight loss has been advocated to 
treat patients with NAFLD in all guidelines (Tables 3 and 
4). Indeed, weight loss has been reported as a keystone 
element in improving the histology features of NASH
[39,40]
.
According to the AISF position paper
[7], the best 
therapeutic approach is an adequate lifestyle change 
focused on weight loss and achieved by physical activity 
(aerobic activities and resistance training) and healthy 
diet. In particular, an energy restriction obtained with 
a low calorie (1200­1600 kcal/d), low fat (less than 
10% of saturated fatty acid), low carbohydrate diet (< 
50% of total kcal) is suggested. A Mediterranean diet 
is recommended as the most effective dietary option to 
induce a weight loss together with beneicial effects on all 
cardio­metabolic risk factors associated with NAFLD[7].
The Asia­Pacific guidelines agree with a lifestyle 
intervention strategy for the treatment of NAFLD, focu-
sing the attention on the timing of weight loss that should 
be gradual because of the deleterious effect of crash 
diets on NASH. Very low-calorie diets are considered 




Also, the EASL[3], NICE[4], and AASLD[8] guidelines 
recommend structured programmes aimed at lifestyle 
changes towards a healthy diet and habitual physical 
activity. According to all of these guidelines, a 7%­10% 
weight loss is the target of most lifestyle interventions. 
Pharmacological treatment: (1) Who to treat: 
According to the EASL guidelines[3], pharmacological 
therapy should be reserved for: Progressive NASH (brid­
ging fibrosis and cirrhosis); early­stage NASH at high 
risk for disease progression (age > 50 years, metabolic 
syndrome, diabetes mellitus or increased ALT)[41]; 
active NASH with high necroinflammatory activities
[42]
. 
Similarly, in the AASLD and Asia­Pacific guidelines, a 
pharmacological approach is recommended only for 
patients with NASH and ibrosis[8]. In the NICE guidance, 
just people with an advanced liver fibrosis (ELF test > 
10.51) are proposed for pharmacological treatment[4]. 
In the AISF position paper, drug therapy is suggested for 
patients who are at high risk for disease progression
[7]
. (2) 
Pharmacologic treatment: Currently, no drugs have been 
approved for the treatment of NASH by the US Food 
and Drug Administration or by the European Medicines 
Agency. All guidelines acknowledge that any medicines 
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prescribed explicitly for NAFLD should be considered 
as an off­label treatment and that the decision should 
be discussed with the patient, carefully balancing the 
benefits and the safety. However, the guidelines are 
widely discordant about possibly helpful drugs (Table 5). 
Metformin: Due to the evidence of its limited eficacy 
in improving the histological features of NAFLD
[43­45]
, 
metformin is not recommended by any guidelines to 
speciically treat NAFLD[3­8]. 
Pioglitazone: Pioglitazone, a thiazolidinedione, is 
a peroxisome proliferator­activated receptor (PPAR) 
gamma agonist with insulin-sensitising effects. Treat-
ment with pioglitazone improves insulin sensitivity, amino-
transferases, steatosis, inlammation, and ballooning in 
patients with NASH and prediabetes or T2DM[46]. The 
PIVENS trial (a large multicenter RCT) compared low 
dose pioglitazone (30 mg/d) vs vitamin E (800 UI/d) vs 
placebo for two years in patients without overt diabetes. 
Pioglitazone improved all histological features (except 
for fibrosis) and achieved resolution of NASH more 
often than placebo[47]. The histological benefit occurred 
together with ALT improvement and partial correction 
of insulin resistance. The main side effects of glitazones 
are weight gain
[48­51], and bone fractures in women[52]. 
The use of pioglitazone for the treatment of NAFLD is 
endorsed both by the NICE and AASLD guidelines, with 
significant limitations. In the first case, pioglitazone 
should be prescribed only in second and third level 
centres, after a careful evaluation
[4]
. In the latter case, 
pioglitazone is reserved for patients with biopsy­proven 
NASH
[8]. The EASL guidelines are more cautious, 
generically suggesting to consider pioglitazone for the 
treatment of diabetes in patients with a concurrent 
NAFLD
[3]. Even the Asia­Paciic and the Italian guidelines 
acknowledge the potential beneits of pioglitazone, how­
ever, suggest that more evidence should be available 
before a irm recommendation can be made[6,7].
Vitamin E: Vitamin E is an anti­oxidant and has been 
investigated to treat NASH. In the PIVENS trial, vitamin 
E at a dose of 800 IU/d of α­tocopherol for 96 wk was 
associated with a decrease in serum aminotransferases 
and histological improvement in steatosis, inlammation, 
EASL NICE Asia-Paciic AISF AASLD
Non-invasive NFS and FIB-4 upon 
diagnosis. If inconclusive, 
perform transient 
elastography
ELF blood test Combination of serum 
tests and imaging tools 
(no speciication about the 
preferred tests)
NFS + FIB-4 upon 
diagnosis. If inconclusive, 
perform transient 
elastography
NFS, FIB-4 and transient 
elastography (or MRE) 
upon diagnosis
Follow up Negative markers > 
reassess every 2 yr; 
Fibrosis or abnormal 
liver enzymes > reassess 
every year; Cirrhosis-> 
surveillance every 6 mo
Negative ELF test, > 
reassess every 3 yr; 
Positive ELF test > liver 
biopsy
No information provided Negative markers > 
reassess every 2 yr; 
Fibrosis or abnormal 
liver enzymes > reassess 
every year; Cirrhosis > 
surveillance every 6 mo
No information provided
Table 3  Comparison of recommendations about non-invasive evaluation of ibrosis and follow up strategies
EASL: European Association for the Study of the Liver; NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the study of 
the Liver; AASLD: American Association for the Study of Liver Diseases; NFS: NAFLD ibrosis score; FIB-4: Fibrosis-4; ELF: Enhanced Liver Fibrosis; MRE: 
Magnetic resonance elastography.




weight loss of 500-1000 g/wk 
with a 7%-10% total weight 
loss
Main recommendations on 
diet of NICE’s obesity and 
preventing excess weight 
gain guidelines
500-1000 kcal deicit 1200-1600 kcal/d;
fat-low (< 30% of total 
calories);





Aerobic and resistance training 
(150-200 min/wk in 3-5 
sessions)
Main recommendation 
of on physical activity 
of NICE’s obesity and 
preventing excess weight 
gain guidelines
Aerobic and resistance 
training
Aerobic and resistance 
training
Aerobic and resistance 




Low-to-moderate fat and 
moderate-to-high carbohydrate 
intake
No speciic suggestions All, excluding very low-
calorie diets




Table 4  Guidance statements about lifestyle interventions
EASL: European Association for the Study of the Liver; NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the Study of 
the Liver; AASLD: American Association for the Study of Liver Diseases.
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and ballooning and resolution of steatohepatitis in adults 
with NASH
[47]. Long­term safety of vitamin E is under 
dispute, with two different meta-analyses leading to 
conlicting results when analysing the all­cause mortality 
in patients treated with t doses of > 800 IU/d[51,52]. 
Similarly to pioglitazone, vitamin E is recommended by 
the NICE and AASLD guidelines (limited to biopsy­proven 
NASH in the latter case)
[4,8]. EASL and AISF guidelines 
call for more evidence before any recommendation[3,7], 
while Asia­Pacific guidelines advice against the use of 




Glucagon­like peptide­1 (GLP­1) analogues: Incretin­
mimetics, acting on the glucose-insulin interplay have 
shown favourable results in pre­marketing studies on 
liver enzymes
[53]. Also, in a published randomised, 
placebo­controlled trial consisting of 52 patients with 
biopsy­proven NASH, liraglutide administered sub­
cutaneously once­daily for 48 wk was associated with 
greater resolution of NASH and less progression of 
ibrosis[54]. Both the AASLD and NICE recommendations 
state that there is still too few evidence to support the 
use of GLP­1 analogues to speciically treat liver disease 
in patients with NAFLD
[4,8]
. The remaining guidelines 
also agree on this point, however also state that further 
evidence may prove the efficacy of these drugs. In 
particular, the APASL guidelines consider some more 
elements in their recommendations. On the one hand, 
GLP­1 agonists appeared to reduce glycated haemoglobin 
more efficiently in Asian patients with type 2 diabetes 
mellitus
[55]. On the other hand, there has been no study 
on Asian NASH patients, even if the pharmacokinetics 
of GLP­1 agonists do not appear to differ between 




Statins: Historically, the use of statins in patients with 
chronic liver diseases has been considered as potentially 
troublesome due to the risk of hepatotoxicity. At the same 
time, a considerable portion of NAFLD patients usually 
receives statins because of their multiple cardiovascular 
risk factors. Consequently, the primary concern of the 
guidelines is the safety of statins. In this regard, a recent 
review underlined the safety of statin and their eficacy 
in reducing the associated cardiovascular morbidity 
in patients with NAFLD, including those with slightly 
elevated alanine transaminases (up to 3 × reference upper 
limit)
[58]. All of the guidelines agree about the safety 
of prescribing statins (or continuing an ongoing statin 
therapy) in patients with NAFLD, even with compensated 
cirrhosis. However, routine prescription of a statin is not 
recommended in patients with decompensated cirrhosis 
and acute liver failure
[59,60]
.
Silymarin: Silymarinis a complex mixture of six major 
flavonolignans (silybins A and B, isosilybins A and B, 
silychristin, and silydianin), as well as other minor poly-
phenolic compounds
[61].In a randomised, double­blinded, 
placebo­controlled study on patients with biopsy­proven 
NASH, silymarin dosage of 700 mg three times daily 
for 48 wk resulted in a significantly higher percentage 
of fibrosis reduction compared with placebo (22.4% 
vs 6.0%, P = 0.023)[62]. The dosage was safe and well 
tolerated
[62]
. Silymarin is mentioned as a potentially use-
ful treatment for NASH in Asia­Pacific guidelines only. 
However, optimal dose and duration still require further 
studies before a full recommendation[6].
Bariatric surgery: In patients unresponsive to lifestyle 
changes and pharmacotherapy, bariatric surgery is an 
option for reducing weight and metabolic complications, 
with stable results in the long­term[63]. Bariatric surgery 
can also improve liver histology, both regarding steatosis 
and ballooning[64,65] and ibrosis[65]. However, the presence 
EASL NICE ASIA-PACIFIC AISF AASLD
Metformin Insuficient evidence Not beneicial Not beneicial Not mentioned Not beneicial
Vitamin E Insuficient evidence Consider use regardless of 
diabetes





Consider use in selected 
diabetic patients
Consider pioglitazone 
in adults regardless of 
diabetes





in biopsy-proven NASH 
(regardless of diabetes)
PUFA Not beneicial Insuficient evidence Not beneicial Not mentioned Not beneicial










UDCA Not beneicial Not beneicial Not mentioned Not mentioned Not beneicial
Obetycolic 
acid
Scarce evidence Not mentioned waiting for ongoing RCT 
results
Waiting for ongoing RCT 
results
Insuficient evidence
Silymarin Not mentioned Not mentioned insuficient evidence, 
potentially useful
Not mentioned Not mentioned
Statins Safe but not beneicial Safe but not beneicial Safe but not beneicial Safe but not beneicial Safe but not beneicial
Table 5  Recommendations about pharmacological treatment of non-alcoholic fatty liver disease
EASL: European Association for the Study of the Liver; NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the Study of 
the Liver; AASLD: American Association for the Study of Liver Diseases; PPAR: Peroxisome proliferator-activated receptors; PUFA: Poly-unsaturated fatty 
acids; GLP-1: Glucagon-like peptide-1.
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of established cirrhosis is associated with peri­operative 
risks. In particular, in the analysis performed from the 
Nationwide Inpatient Sample (1998­2007), mortality 
was higher in patients with compensated cirrhosis (0.9%) 
and much higher in those with decompensated cirrhosis 
(16.3%)[66]. No robust data on the comparative effects of 
different bariatric procedures on liver fat are available in 
the literature. 
Based on the evidence as mentioned earlier, the EASL 
guidelines consider bariatric surgery an option in patients 
unresponsive to lifestyle changes and pharmacotherapy, 
for reducing weight and metabolic complications[3]. 
Guidance statements by the AASLD also consider a role 
of foregut bariatric surgery in otherwise eligible obese 
individuals with NAFLD or NASH
[8]
.
The Asia­Pacific recommendation limits the role of 
bariatric surgery only to patients with class Ⅱ obesity (BMI 
> 32.5 kg/m2 in Asians and 35 kg/m2 in Caucasians)[6]. 
AISF and NICE guidelines do not mention bariatric 
surgery.
Liver transplantation: NASH is becoming the most 
common indication to liver transplantation in Western 
Countries
[67]. Because of the high prevalence of obe­
sity, sarcopenia, cardiovascular disease and chronic 
kidney disease among patients with NASH, there is a 
higher frequency of post-transplant complications and 
increased graft loss
[68,69]. Because of the risk of pro­
longed ventilation, poor wound healing, higher rate of 
primary graft non-function, and increased infectious 
complications, patients with severe obesity (BMI > 40 
kg/m
2) may even be considered unit for liver trans­
plantation, unless efforts are made preoperatively to 
reduce body weight with individualized plans of lifestyle 
modiications[70].
AISF and NICE guidance do not mention liver trans­
plantation. All of the remaining guidelines agree that 
liver transplantation is an acceptable procedure in NASH 
patients with an end-stage liver disease, with the same 




The comparative analysis of the most recent international 
guidelines for the management of NAFLD showed some 
common orientation between the different recommen­
dations, as well as diverging points. The most notable 
differences involved: the identification of the alcohol 
threshold defining NAFLD, the screening strategies in 
high­risk populations, the preferred non­invasive bio­
markers for the assessment of advanced fibrosis, and 
the pharmacological treatment. These differences should 
not be necessarily seen as a limitation, but rather an 
expression of the geographical differences in genetic 
predisposition to NAFLD, lifestyle habits, healthcare 
systems. Arguably, the similarity in the recommendations 
could greatly help in ensuring homogenous management 
of NALFD all over the world, with favourable repercus­
sions both in clinical practice and in clinical trials. In 
the next years, we might see a trend toward more 
homogenous guidelines thanks to the increasing body 
of evidence. In particular, the advancements in the 
imaging technologies could lead to new and widely ac-
cepted noninvasive methods to assess advanced liver 
fibrosis. Moreover, some clinical trials are investigating 
potentially effective drugs. If positive, the currently 
diverging pharmacological recommendations may reach 
a higher concordance. NAFLD is becoming a leading ield 
of research in hepatology: new evidence is destined to 
change the current landscape of knowledge, prompting 
greater beneits to the patients as well as changes in the 
recommendations for clinical practice.
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